Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARAGMOS: High Cabergoline Dosage in Microprolactinomas
NCT07463235Phase 3Recruiting
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cabergoline in prolactinoma, sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Started Mar 2026; status: recruiting.
02
Drugs
cabergoline
03
Conditions
prolactinoma
Beyond the preview
Go deeper on NCT07463235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07463235.